Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Authors :: Charpentier C
Roquebert B
Delelis O
Larrouy L
Matheron S
Tubiana R
Karmochkine M
Duval X
Chêne G
Storto A
Collin G
Bénard A
Damond F
Mouscadet JF
Brun-Vézinet F
Descamps D
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2011 Mar; Vol. 55 (3), pp. 1293-5. Date of Electronic Publication: 2010 Dec 28.
Publication Year :: 2011
Abstract: We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Subjects :: Drug Resistance, Viral genetics
Genotype
HIV Infections drug therapy
HIV Infections genetics
HIV-2 pathogenicity
Humans
Molecular Sequence Data
Raltegravir Potassium
Antiviral Agents therapeutic use
HIV Integrase genetics
HIV-2 drug effects
Pyrrolidinones therapeutic use

Full Text Access

Tools